Company Focus
Eli Lilly & Company
Latest Eli Lilly & Company News
Pharmaceutical
The obesity drug market has experienced a seismic shift in recent years, with Novo Nordisk's Wegovy (semaglutide) and Eli Lilly's Mounjaro (tirzepatide) revolutionizing the way the condition is treated. 11 April 2025
Related News
Insights
Company Spotlight
An American biotech company developing solutions that treat urothelial and specialty cancers.
Latest News & Features of interest to Eli Lilly & Company
Biotechnology
Shares of USA-based NextCure slumped 26% to $0.50 on Monday, after the company announced a strategic partnership with China-based Simcere Zaiming, subsidiary of Simcere Pharmaceutical Group Ltd to develop a therapy for the treatment of solid tumors. 17 June 2025
Biotechnology
Israel’s Teva Pharmaceutical Industries and Shanghai Fosun Pharmaceutical have entered a strategic partnership for the development of investigational TEV-56278, an anti-PD1-IL2 ATTENUKINE therapy. 17 June 2025
Biotechnology
Scientists at The Institute of Cancer Research, London, claim to have discovered what may cause some treatments to stop working in people living with bowel cancer. 16 June 2025
Pharmaceutical
Supernus Pharmaceuticals is to buy Sage Therapeutics for total consideration of around $795 million. 16 June 2025
Biotechnology
A second case of acute liver failure (ALF) resulting in the death has been reported in a young recipient of Elevidys (delandistrogene moxeparvovec-rokl), the only approved gene therapy for Duchenne muscular dystrophy. 16 June 2025
Biotechnology
Swiss pharma giant Roche announced today its decision to proceed with Phase III development of prasinezumab, an investigational anti-alpha-synuclein antibody, in early-stage Parkinson’s disease (PD). 16 June 2025
Biotechnology
Boston, USA-based biotech Solu Therapeutics today announced the appointment of Enda Moran as chief operating officer (COO). 16 June 2025
Biotechnology
Californian biotech Jasper Therapeutics presented data from the 180mg cohort of the company’s SPOTLIGHT Phase Ib/IIa study of subcutaneous briquilimab in adult participants with chronic inducible urticaria (CIndU) at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress. 16 June 2025
Biotechnology
Notable research news last week included US biopharma Avidity Biosciences announcing a positive update on its muscular dystrophy candidate delpacibart braxlosiran (del-brax), and Dutch firm NewAmsterdam released new Phase III on its investigational Alzheimer’s drug obicetrapib. US Health Secretary Robert F Kennedy Jr announced he has dismissed an independent panel of vaccine experts in order to restore trust in vaccines. Also of note, Merck & Co gained US food and Drug Administration (FDA) for its Enflonsia for the prevention of respiratory syncytial virus (RSV). 15 June 2025
Biotechnology
The Food and Drug Administration approved US pharma giant Merck & Co’s mega-blockbuster cancer drug Keytruda (pembrolizumab) for a new indication. 13 June 2025
Latest In Brief for Eli Lilly & Company
Biotechnology
South Korea’s LigaChem Biosciences has signed two antibody licensing agreements with US biotech NovaRock Biotherapeutics, reports Korea Biomedical Review. 12 June 2025
Latest Related Ones To Watch News
US pharma major Eli Lilly (today announced a definitive agreement to acquire Verve Therapeutics, a Boston-based clinical-stage company developing genetic medicines for cardiovascular disease, sending Verve’s shares up 77.7% to $11.15 in premarket trading. 17 June 2025
16 June 2025
12 June 2025
Related Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze